<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2346">
  <stage>Registered</stage>
  <submitdate>5/05/2009</submitdate>
  <approvaldate>5/05/2009</approvaldate>
  <nctid>NCT00893971</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects</studytitle>
    <scientifictitle>A Randomized, Double-blind, Single Dose, Four-period, Four-treatment, Cross-over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PT0030901</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PT001
Treatment: drugs - PT005
Treatment: drugs - PT003
Treatment: drugs - PT001 + PT005

Experimental: 1 - Inhaled PT001 18 µg

Experimental: 2 - Inhaled PT005 2.4 µg

Experimental: 3 - Inhaled PT003 (PT001 18 µg / 2.4 µg PT005)

Experimental: 4 - PT001 18 µg + PT005 2.4 µg


Treatment: drugs: PT001
Inhaled PT001, single dose

Treatment: drugs: PT005
Inhaled PT005, single dose

Treatment: drugs: PT003
Inhaled PT003, single dose

Treatment: drugs: PT001 + PT005
Inhaled PT001 + PT005, single dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Symptoms of Dry Mouth - Number of participants reporting dry mouth at 12 hours post-dose</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Symptoms of Tremor - Number of participants reporting tremor at 12 hours post-dose</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Blood Chemistry Change From Baseline - Series of 11 blood chemistries assessed throughout the study</outcome>
      <timepoint>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Hematology Change From Baseline - Hematology assessments taken throughout the study Hematocrit</outcome>
      <timepoint>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Hematology Change From Baseline - Hematology assessments taken throughout the study</outcome>
      <timepoint>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Hematology Change From Baseline - Hematology assessments taken throughout the study Hemoglobin</outcome>
      <timepoint>24 hours post dose for sentinel subjects, 12 hours post dose for subsequent subjects</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Heart Rate Change From Baseline - Change from baseline for heart rate 12-hours post-dose Heart rate (bpm)</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Vital Sign Change Baseline; Blood Pressure - Vital sign change baseline; blood pressure</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Vital Sign Change From Baseline, SpO2 - Vital Sign Change from baseline 12-hours post-dose SpO2 (%)</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>ECG Change From Baseline - Change from baseline for ECG parameters 12-hours post-dose Ventricular rate (bpm)</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>ECG Change From Baseline - Change from baseline for ECG parameters 12-hours post-dose</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Spirometry Change From Baseline - Change from baseline for spirometery measures 12-hours post-dose</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Spirometry Change From Baseline - Change from baseline for spirometery measures 12-hours post-dose (FEV1 % predicted)</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Spirometry Change From Baseline - Change from baseline for spirometery measures 12-hours post-dose FEV/FVC (%)</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Spirometry Change From Baseline - Change from baseline for spirometery measures 12-hours post-dose PEFR (L/min)</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Serum Potassium Change From Baseline</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Glycopyrrolate PK Parameters - Various pharmacokinetic parameters for plasma glycopyrrolate</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Glycopyrrolate PK Parameters AUC0-inf (h*pg/mL) - Various pharmacokinetic parameters for plasma glycopyrrolate</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Glycopyrrolate PK Parameters (Tmax) - Various pharmacokinetic parameters for plasma glycopyrrolate</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Glycopyrrolate PK Parameters (t1/2) - Various pharmacokinetic parameters for plasma glycopyrrolate</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Glycopyrrolate PK Parameters Cmax (pg/mL) - Various pharmacokinetic parameters for plasma glycopyrrolate</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Glycopyrrolate PK Parameters (ke) - Various pharmacokinetic parameters for plasma glycopyrrolate</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Formoterol PK Parameters - Various pharmacokinetic parameters for plasma formoterol</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Formoterol PK Parameters AUC0-inf (h*pg/mL) - Various pharmacokinetic parameters for plasma formoterol</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Formoterol PK Parameters (Tmax) - Various pharmacokinetic parameters for plasma formoterol</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Formoterol PK Parameters (t1/2) - Various pharmacokinetic parameters for plasma formoterol</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Formoterol PK Parameters (Cmax) - Pharmacokinetic parameters for plasma formoterol Cmax</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma Formoterol PK Parameters (ke) - Pharmacokinetic parameters for plasma formoterol ke</outcome>
      <timepoint>Concentrations were measured at pre-dose and 2,5,15, and 30 minutes post dose as well as 1,2,4,6,8, and 12 hours post dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provide signed written informed consent

          -  18-55 years of age

          -  Healthy subjects confirmed by medical history, physical examination, vital signs,
             pulmonary function tests, electrocardiogram and clinical laboratory tests

          -  Female subjects of child-bearing potential who are sexually active must be willing to
             undergo a pregnancy test and agree to use two forms of contraception

          -  Body mass index (BMI) between 18.5 and 30, inclusive

          -  Non-smokers for at least 6 months prior to screening

          -  Pulmonary function tests within normal limits

          -  Willing to remain at the study center for at least 12-24 hours on each test day

          -  Venous access in both arms to allow collection of numerous blood samples</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Women who are pregnant or lactating

          -  Clinically significant medical conditions

          -  Viral illness within the last 30 days

          -  Symptomatic prostatic hypertrophy or bladder neck obstruction

          -  Known narrow-angle glaucoma

          -  History of bowel obstruction

          -  Clinically significant abnormal electrocardiogram

          -  Positive Hepatitis B surface antigen or positive Hepatitis C antibody

          -  Positive screening test for HIV antibodies

          -  History of hypersensitivity to any beta2-agonists, anticholinergics, or any component
             of the MDI

          -  Known or suspected history of alcohol or drug abuse within the last 2-years

          -  Greater than normal alcohol consumption

          -  Ingestion of any poppy seeds within the 48 hours prior to the screening

          -  Ingestion of any poppy seeds within the 48 hours prior to, or any alcohol, xanthines
             or grapefruit-containing foods or beverages within the 24 hours prior to, or during,
             each confinement

          -  Positive breath alcohol result

          -  Positive urine drug screen

          -  Use of any beta2-agonists,or anticholinergics prior to the recruitment interview

          -  Lower respiratory tract infections requiring antibiotics in the previous 6 weeks

          -  Use of any other prescription medication

          -  Use of any over the counter product, herbal product, diet aid, hormone supplement

          -  Donation &gt; 450 ml of blood within 8 weeks of first treatment dose

          -  Clinically significant vital sign abnormality

          -  Clinically significant biochemical, hematological or urinalysis abnormality

          -  Affiliations with investigator site

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives prior to screening, whichever is
             longer</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>16</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Dr Joanne Marjason - Herston</hospital>
    <postcode>4006 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pearl Therapeutics, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety of a single dose of PT003 compared with
      single doses of PT001 and PT005, and compared with PT001 plus PT005 delivered together as two
      separate single doses in healthy subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00893971</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Colin Reisner, M.D.</name>
      <address>Pearl Therapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>